ReviewInfluenza and other respiratory viruses2018
Standardisation of inactivated influenza vaccines-Learning from history.
Review in Influenza and other respiratory viruses, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Antineuraminidase Antibody Responses in Older Adults After Consecutive Vaccinations With Enhanced Influenza Vaccines: A Randomized Controlled Trial.The Journal of infectious diseases · 2026Trial
- A Monoclonal Antibody ELISA-Based Assay for Measuring the Potency of Candidate H5 Clade 2.3.4.4b Pandemic Influenza Vaccines.Influenza and other respiratory viruses · 2026Article
- Evaluation of Immunogenicity of Seasonal Influenza Split HA Vaccines Involved With Changes of Vaccine Strains Using Mouse and Human Sera.Microbiology and immunology · 2026Article
- Article
- A Rapid Virus-Free Method for Producing Influenza HA Immunogen Needed for Preparation of Influenza Vaccine Potency Antisera Reagents.Influenza and other respiratory viruses · 2024Article
- Developments and current challenges in the process of cell culture-based seasonal influenza vaccine manufacture in Japan.Global health & medicine · 2024Review
- Antibody-independent surface plasmon resonance assays for influenza vaccine quality control.Applied microbiology and biotechnology · 2024Review
- Article
- Does Vaccine-Induced Maternally-Derived Immunity Protect Swine Offspring against Influenza a Viruses? A Systematic Review and Meta-Analysis of Challenge Trials from 1990 to May 2021.Animals : an open access journal from MDPI · 2023Review
- Neutralizing and protective murine monoclonal antibodies to the hemagglutinin of influenza H5 clades 2.3.2.1 and 2.3.4.4.Influenza and other respiratory viruses · 2023Article
- Rapid determination of influenza vaccine potency by an SPR-based method using subtype or lineage-specific monoclonal antibodies.Frontiers in immunology · 2023Article
- Selective reversed-phase high-performance liquid chromatography method for the determination of intact SARS-CoV-2 spike protein.Journal of chromatography. A · 2022Article
- Development of an ELISA-Based Potency Assay for Inactivated Influenza Vaccines Using Cross-Reactive Nanobodies.Vaccines · 2022Article
- Global Pandemic Preparedness: Optimizing Our Capabilities and the Influenza Experience.Vaccines · 2022Review
- An Overview of Influenza Viruses and Vaccines.Vaccines · 2021Review
- Broad Reactivity Single Domain Antibodies against Influenza Virus and Their Applications to Vaccine Potency Testing and Immunotherapy.Biomolecules · 2021Review
- Limited Tryptic Digestion-Isotope Dilution Mass Spectrometry (LTD-IDMS): A Reagent-Free Analytical Assay To Quantify Hemagglutinin of A(H5N1) Vaccine Material.Analytical chemistry · 2020Article
- Pandemic Influenza Vaccines: What did We Learn from the 2009 Pandemic and are We Better Prepared Now?Vaccines · 2020Article
- Hemagglutinin Quantitative ELISA-based Potency Assay for Trivalent Seasonal Influenza Vaccine Using Group-Specific Universal Monoclonal Antibodies.Scientific reports · 2019Article
- Reference antigen-free and antibody-free LTD-IDMS assay for influenza H7N9 vaccine in vitro potency determination.Vaccine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The single radial immunodiffusion assay has been the accepted method for determining the potency of inactivated influenza vaccines since 1978. The worldwide adoption of this assay for vaccine standardisation was facilitated through collaborative studies that demonstrated a high level of reproducibility and its applicability to the different types of influenza vaccine being produced at that time. Clinical evidence indicated the relevance of SRID as a potency assay. Unique features of the SRID assay are likely responsible for its longevity even as newer technologies for vaccine characterisation have been developed and refined. Nevertheless, there are significant limitations to the SRID assay that indicate the need for improvement, and there has been a substantial amount of work undertaken in recent years to develop and evaluate alternative potency assays, including collaborative studies involving research laboratories, regulatory agencies and vaccine manufacturers. Here, we provide an overview of the history of inactivated influenza vaccine potency testing, the current state of alternative assay development and the some of the major challenges to be overcome before implementation of new assays for potency determination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.